Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 12/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | SFRP1 | Q8N474 | 4/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015103 | 0.88 | SFRP1 (0.46) | GPR119SFRP1STS | |
| SCHEMBL1015101 | 0.88 | SFRP1 (0.46) | GPR119SFRP1STS | |
| SCHEMBL1014796 | 0.87 | STS (0.42) | TGFBR1GPR119SFRP1STS | |
| SCHEMBL12954783 | 0.81 | GPR119 (0.46) | TGFBR1GPR119SFRP1STS | |
| SCHEMBL13230238 | 0.81 | GPR119 (0.40) | TGFBR1GPR119STSBRD4 | |
| SCHEMBL2473362 | 0.78 | PDE4B (0.50) | TGFBR1GPR119 | |
| SCHEMBL1016558 | 0.78 | GPR119 (0.45) | GPR119SFRP1STS | |
| SCHEMBL4070951 | 0.78 | USP30 (0.51) | GPR119STS | |
| SCHEMBL13210960 | 0.77 | DRD2 (0.35) | BRD4 | |
| SCHEMBL1014623 | 0.77 | PDE4B (0.47) | TGFBR1GPR119SFRP1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081890-B1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2081890-A1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
| WO-2008055847-A1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055847-A1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | HTR6, HTR1B, HTR1F | TGFBR1 3794/4885GPR119 138/4885SFRP1 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.